Lucas Morin1, Johan Fastbom1, Marie-Laure Laroche2,3, Kristina Johnell1. 1. Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden. 2. Centre Hospitalier Universitaire de Limoges, Service de Pharmacologie, Toxicologie et Pharmacovigilance, Limoges, France. 3. Université de Limoges, Faculté de Médecine, Limoges, France.
Abstract
AIMS: The aim was to investigate the prevalence of potentially inappropriate medication use among older people in Sweden according to five different published sets of explicit criteria from Europe and the US. METHODS: This was a nationwide cross-sectional, register-based study across the whole of Sweden in 2008. All individuals aged 65 years and older were included (n = 1 346 709, both community-dwelling and institutionalized persons). We applied all drug-specific criteria included in the 2012 Beers Criteria, the Laroche's list, the PRISCUS list, the NORGEP criteria and the Swedish National Board of Health and Welfare criteria. The main outcome was the potentially inappropriate drug use according to each set of criteria, separately and combined. Multivariate logistic regression models were used to identify individual factors associated with the use of potentially inappropriate drugs. RESULTS: The prevalence of potentially inappropriate medication use varied between the explicit criteria from 16% (NORGEP criteria) to 24% (2012 Beers criteria). Overall, 38% of the older people were exposed to potentially inappropriate drug use by at least one of the five sets of criteria. While controlling for other possible covariates, female gender, institutionalization and polypharmacy were systematically associated with inappropriate drug use, regardless of the set of explicit criteria we considered. CONCLUSION: Although explicit criteria for inappropriate drug use among older people have been reported to be quite different in their content, they provide similar measures of the prevalence of potentially inappropriate drug use at the population level.
AIMS: The aim was to investigate the prevalence of potentially inappropriate medication use among older people in Sweden according to five different published sets of explicit criteria from Europe and the US. METHODS: This was a nationwide cross-sectional, register-based study across the whole of Sweden in 2008. All individuals aged 65 years and older were included (n = 1 346 709, both community-dwelling and institutionalized persons). We applied all drug-specific criteria included in the 2012 Beers Criteria, the Laroche's list, the PRISCUS list, the NORGEP criteria and the Swedish National Board of Health and Welfare criteria. The main outcome was the potentially inappropriate drug use according to each set of criteria, separately and combined. Multivariate logistic regression models were used to identify individual factors associated with the use of potentially inappropriate drugs. RESULTS: The prevalence of potentially inappropriate medication use varied between the explicit criteria from 16% (NORGEP criteria) to 24% (2012 Beers criteria). Overall, 38% of the older people were exposed to potentially inappropriate drug use by at least one of the five sets of criteria. While controlling for other possible covariates, female gender, institutionalization and polypharmacy were systematically associated with inappropriate drug use, regardless of the set of explicit criteria we considered. CONCLUSION: Although explicit criteria for inappropriate drug use among older people have been reported to be quite different in their content, they provide similar measures of the prevalence of potentially inappropriate drug use at the population level.
Authors: Daniel S Budnitz; Daniel A Pollock; Kelly N Weidenbach; Aaron B Mendelsohn; Thomas J Schroeder; Joseph L Annest Journal: JAMA Date: 2006-10-18 Impact factor: 56.272
Authors: Sture Rognstad; Mette Brekke; Arne Fetveit; Olav Spigset; Torgeir Bruun Wyller; Jørund Straand Journal: Scand J Prim Health Care Date: 2009 Impact factor: 2.581
Authors: Dedan Opondo; Saied Eslami; Stefan Visscher; Sophia E de Rooij; Robert Verheij; Joke C Korevaar; Ameen Abu-Hanna Journal: PLoS One Date: 2012-08-22 Impact factor: 3.240
Authors: Stefan Varga; Matthew Alcusky; Scott W Keith; Sarah E Hegarty; Stefano Del Canale; Marco Lombardi; Vittorio Maio Journal: Br J Clin Pharmacol Date: 2017-08-04 Impact factor: 4.335
Authors: Dana Clarissa Muhlack; Liesa Katharina Hoppe; Christian Stock; Walter E Haefeli; Hermann Brenner; Ben Schöttker Journal: Eur J Clin Pharmacol Date: 2018-08-29 Impact factor: 2.953
Authors: Natacha Christina de Araújo; Erika Aparecida Silveira; Brenda Godoi Mota; Rafael Alves Guimarães; Ana Carolina Figueiredo Modesto; Valéria Pagotto Journal: Int J Clin Pharm Date: 2022-07-27
Authors: Filipa Alves da Costa; Catarina Periquito; Maria Clara Carneiro; Pedro Oliveira; Ana Isabel Fernandes; Patrícia Cavaco-Silva Journal: Int J Clin Pharm Date: 2016-06-24